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Abstract
Background: Postpartum hemorrhage (PPH) is a leading cause of maternal death in sub-Saharan Africa. Although the World
Health Organization recommends use of oxytocin for prevention of PPH, misoprostol use is increasingly common owing to
advantages in shelf life and potential for sublingual administration. There is a lack of data about the comparative efficacy of
oxytocin and sublingual misoprostol, particularly at the recommended dose of 600 mg, for prevention of PPH during active
management of labor.
Methods and Findings: We performed a double-blind, double-dummy randomized controlled non-inferiority trial between
23 September 2012 and 9 September 2013 at Mbarara Regional Referral Hospital in Uganda. We randomized 1,140 women
to receive 600 mg of misoprostol sublingually or 10 IU of oxytocin intramuscularly, along with matching placebos for the
treatment they did not receive. Our primary outcome of interest was PPH, defined as measured blood loss $500 ml within
24 h of delivery. Secondary outcomes included measured blood loss$1,000 ml; mean measured blood loss at 1, 2, and 24 h
after delivery; death; requirement for blood transfusion; hemoglobin changes; and use of additional uterotonics. At 24 h
postpartum, primary PPH occurred in 163 (28.6%) participants in the misoprostol group and 99 (17.4%) participants in the
oxytocin group (relative risk [RR] 1.64, 95% CI 1.32 to 2.05, p,0.001; absolute risk difference 11.2%, 95% CI 6.44 to 16.1).
Severe PPH occurred in 20 (3.6%) and 15 (2.7%) participants in the misoprostol and oxytocin groups, respectively (RR 1.33,
95% CI 0.69 to 2.58, p= 0.391; absolute risk difference 0.9%, 95% CI 21.12 to 2.88). Mean measured blood loss was 341.5 ml
(standard deviation [SD] 206.2) and 304.2 ml (SD 190.8, p= 0.002) at 2 h and 484.7 ml (SD 213.3) and 432.8 ml (SD 203.5, p,
0.001) at 24 h in the misoprostol and oxytocin groups, respectively. There were no significant differences between the two
groups in any other secondary outcomes. Women in the misoprostol group more commonly experienced shivering (RR 1.91,
95% CI 1.65 to 2.21, p,0.001) and fevers (RR 5.20, 95% CI 3.15 to 7.21, p= 0.005). This study was conducted at a regional
referral hospital with capacity for emergency surgery and blood transfusion. High-risk women were excluded from
participation.
Conclusions: Misoprostol 600 mg is inferior to oxytocin 10 IU for prevention of primary PPH in active management of labor.
These data support use of oxytocin in settings where it is available. While not powered to do so, the study found no
significant differences in rate of severe PPH, need for blood transfusion, postpartum hemoglobin, change in hemoglobin, or
use of additional uterotonics between study groups. Further research should focus on clarifying whether and in which sub-
populations use of oxytocin would be preferred over sublingual misoprostol.
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Introduction
Of the estimated 287,000 maternal deaths worldwide, 85%
occur in low- and middle-income countries [1]. In Uganda, the
maternal mortality ratio is among the highest in the world,
estimated at over 360 for every 100,000 women [2] and claiming
the lives of over 5,500 mothers annually. Twenty-five percent of
these deaths occur because of postpartum hemorrhage (PPH)
within 24 h of delivery [3].
Oxytocin, a hormone that stimulates uterine contractions and
limits uterine bleeding after birth, is the standard of care for
prevention of PPH during the third stage of labor [4]. The use of
oxytocin in low-income countries, however, has historically been
limited by a number of factors including a perceived requirement
for administration by skilled personnel, cold chain storage, and a
requirement for sterile syringes and needles [5,6]. Recent work has
begun to challenge these limitations, as exemplified by effective
administration of oxytocin by lay community health officers during
home births [7].
Misoprostol, a synthetic prostaglandin with uterotonic proper-
ties, has been proposed as an alternative strategy for prevention of
PPH in settings where oxytocin use is not feasible. It has important
advantages over oxytocin, including the potential for oral
administration and a long shelf life at room temperature [8].
Moreover, misoprostol can be administered sublingually, enabling
a more rapid onset of action and greater bioavailability by
avoiding first-pass metabolism [9]. These characteristics have led
civil society organizations in Uganda to champion increased
accessibility and use of misoprostol as a complementary drug to
oxytocin in prevention of PPH [6]. Yet despite these advantages,
sublingual misoprostol remains a second-line option to injectable
uterotonics according to most recommending agencies [4,10]
because of insufficient [11] or conflicting [12] evidence about its
efficacy in the active management of the third stage of labor.
Although prior studies have compared injectable oxytocin with
misoprostol [11], the comparative efficacy of sublingual misopros-
tol versus oxytocin remains largely unknown because prior studies
have focused on oral administration of misoprostol by less skilled
birth attendants [13,14], evaluated oral as opposed to sublingual
administration of misoprostol [15], or evaluated suboptimal doses
of either oxytocin [16], other injectable uterotonics, or misoprostol
[17–19].
We performed a double-blind, double-dummy randomized
controlled non-inferiority trial comparing sublingual misoprostol
versus oxytocin at a publically funded regional referral hospital in
rural, southwestern Uganda. We aimed to elucidate the compar-
ative benefit of oxytocin versus sublingual misoprostol, at the
World Health Organization recommended dose of 600 mg [4], for
prevention of PPH during active management of uncomplicated
labor at a large referral hospital in a resource-limited setting. We
hypothesized that sublingual misoprostol would be non-inferior to
oxytocin for prevention of primary PPH.
Methods
Ethics Statement
This study was approved by the Institutional Review Commit-
tee of Mbarara University of Science and Technology and the
Uganda National Council for Science and Technology. Trial
registration at ClinicalTrials.gov (NCT01866241) was completed
approximately halfway through the study. The delayed registra-
tion was due to the prolonged leave of the single ClinicalTrials.gov
administrator at the principal investigator’s institution.
Study Design and Setting
We conducted a double-blind, double-dummy randomized
controlled non-inferiority trial at Mbarara Regional Referral
Hospital, a publically funded teaching hospital in southwestern
Uganda serving ten districts with a population of over 5 million
people. The hospital employs seven obstetricians and 22 midwives.
Hospital staff perform over 10,000 deliveries annually. Prior to the
study, we performed a retrospective review of hospital records to
estimate rates of attended births, PPH, and maternal mortality.
During that review, we counted 9,027 births over a 10-mo period.
During that period, 2,979 mothers (33%) were recorded to have
had PPH, and 11 mothers died during admission because of
complications of PPH (0.12% of mothers in the review period).
Participants and Recruitment
Midwife research assistants (MRAs) screened laboring mothers
in early active labor on arrival to the prenatal ward. Eligibility
criteria were (1) age above 18 y, (2) 38–41 wk of amenorrhea, and
(3) anticipated uncomplicated vaginal delivery as assessed by
hospital staff. The exclusion criteria were (1) confirmed intrauter-
ine fetal death, (2) self-reported maternal heart disease, (3) current
diagnosis of severe malaria or acute bacterial infection, (4) multiple
pregnancy, (5) induced or augmented labor, (6) elective cesarean
section, (7) antepartum hemorrhage, (8) reported hypersensitivity
to prostaglandins, and (9) altered cognitive status as assessed by
MRA. MRAs obtained informed consent from all eligible
participants after the birth was predicted to be an uncomplicated
vaginal delivery. An MRA trained in human participant research
conducted informed consent procedures with eligible mothers in
the local language in a private area of the hospital. Only mothers
in the early stages of labor (less than 6 cm dilation) were
approached. All consenting participants gave written informed
consent, or for those who could not write, a thumbprint was made
on the consent form.
Randomization, Blinding, and Medicine Preparation
A study biostatistician generated a randomization list with a
block size of ten, totaling 570 participants in each group. The list
was shared only with the study clinical pharmacist, who prepared
the study drugs and placebos. Each participant received a
treatment (600 mg of misoprostol or 10 IU of oxytocin) and
placebo (injection of 1 ml of sterile water or three pills containing
maize starch, methyl hydroxybenzoate, and magnesium stearate)
within 1 min of birth. An independent clinical pharmacist at
Mbarara University of Science and Technology prepared the
corresponding treatments and placebos. Misoprostol 200-mg pills
(Cytotec Searle, United Kingdom) were procured from Laborex
Uganda. Oxytocin (10 IU/1 ml) was procured from Joint Medical
Store (Kampala, Uganda). Before the use of the medications, we
performed bioequivalence testing for both active interventions at
the Ugandan National Chemotherapeutics Research Laboratory.
Bioequivalence for misoprostol ranged from 95.8% to 99.8%, and
for oxytocin ranged from 94.7% to 103.5%. To achieve blinding
of the participants and assessors, both inactive agents were
manufactured and packaged to resemble actual study medicines in
terms of shape, size, and color by Kampala Pharmaceuticals
Industries (Uganda).
Study Procedures
MRAs received opaque envelopes with affixed study codes,
containing both an injection (1 ml of oxytocin 10 IU or its
placebo) and three pills (misoprostol 600 mg or its placebo), which
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were given intramuscularly and sublingually, respectively, within
1 min of delivery. Delayed cord clamping was preferred, and the
placenta was delivered by controlled cord traction or manually if
not delivered within 30 min postpartum, as per Ugandan national
clinical guidelines [20]. Further care was provided by the hospital
clinical care team in collaboration with MRAs in accordance with
national guidelines, which recommend administration of a repeat
dose of parenteral oxytocics along with bladder emptying,
management of lacerations, and uterine massage if bleeding
persists. All mothers were monitored for a minimum of 24 h
postpartum.
Study Measures
A blood sample for complete blood count was drawn
immediately after admission and again prior to hospital discharge,
or before blood transfusion. MRAs recorded vital signs, duration
of second and third stages of labor, secondary use of open-label
uterotonics, placental retention, requirement for blood transfusion,
and side effects, using a standardized data collection form. After
the baby was born, the amniotic fluid was drained immediately. A
clean plastic sheet specifically designed and piloted to collect blood
for this trial was placed under the mother’s buttocks during and
after the third stage of labor. Blood was drained into a calibrated
container to improve accuracy in blood loss measurement [21,22].
All mothers were given preweighed standard sanitary pads to place
in the perineum at all times. These pads were changed and
weighed hourly for the first 6 h, and then every 6 h until 24 h
postpartum. Blood loss was estimated as 1 ml per gram of weight
of the pad after subtracting the dry pad weight, as previously
described [22]. This estimated blood loss was added to the volume
of blood from the plastic sheet. To improve consistency in
estimation of blood loss, standardized electronic scales were used
to weigh soiled sanitary pads.
Study Outcomes
Our primary outcome was primary PPH, defined as maternal
loss of blood $500 ml within 24 h of birth, as conventionally
defined [4]. Secondary outcomes included the following: (1) death;
(2) severe PPH, defined as maternal blood loss $1,000 ml within
24 h of birth; (3) changes in red cell indices during hospitalization,
defined as (a) postpartum hemoglobin ,100 g/l, (b) .10%
decrease between pre- and postpartum hemoglobin, (c) mean
postpartum hemoglobin, and (d) mean postpartum hematocrit; (4)
mean measured blood loss at 1, 2, and 24 h postpartum; (5)
placental retention; (6) requirement for blood transfusion (which is
indicated per clinical protocol at the study site for mothers with a
hemoglobin ,100 g/l and/or severe pallor); (7) requirement for
additional management of PPH, including therapeutic uterotonic
drugs or surgical or radiological procedures; and (8) duration of
the third stage of labor. The outcomes of blood loss at 1 and 2 h
postpartum were post hoc analyses added to enable direct
comparisons with other studies, which have often used those end
points. All patients were assessed for continued blood loss at 2 h
postpartum, when a second blood sample was drawn from
participants for complete blood count, blood type, and cross-
matching. To avoid measurement bias, we used the values from
this measurement to calculate changes in hemoglobin and
hematocrit levels for women who received a subsequent blood
transfusion. We also compared the safety profile of both treatment
groups, including observed rates of shivering, nausea and
vomiting, fever .37.5uC within 24 h of delivery, self-reported
headache, diarrhea, abdominal afterpains, and the use of
analgesics in the postpartum period.
Sample Size and Statistical Analysis
We followed CONSORT guidelines for conducting and
reporting a non-inferiority study [23]. We designed the non-
inferiority study with a 6% absolute risk difference as our non-
inferiority margin (DNI). We selected the non-inferiority margin of
6% based on prior data comparing oxytocin with placebo for
active management of labor that demonstrated a 50% relative
reduction in the rate of PPH with oxytocin versus placebo [24].
Assuming a predicted incidence of PPH of 14% in mothers treated
with prophylactic oxytocin, as reported previously by a well-
powered clinical trial [15], a non-inferiority margin of 6% would
correspond to an upper bound of PPH incidence of 20% among
mothers treated with misoprostol. We chose this upper bound of
non-inferiority so that a 20% PPH rate in the misoprostol arm
would be similar to the rate for women treated with oxytocin and
likely superior to predicted rates of PPH in women not receiving
treatment [25]. Allowing for a two-sided type I error of 5%, we
planned enrollment of 1,140 mothers to enable 90% power to
demonstrate non-inferiority between groups. We compared
dichotomous outcomes between study groups by estimating crude
relative risks (RRs) with 95% confidence intervals, and testing for
differences between treatment groups. We estimated p-values with
chi-squared tests using a level of significance of 0.05. We also
tested for the significance of absolute risk differences using the Z-
test of proportions. For continuous outcomes, we estimated p-
values using Student’s t tests. All primary and secondary outcomes
were analyzed using intention-to-treat analyses (although no
participants were misallocated treatment) [23]. As per the revised
CONSORT guidelines for reporting randomized trials [26], we
assessed for sub-group effects for the following characteristics by
testing the significance of interaction terms in a multivariable
logistic regression model: (1) age (18–35 y and .35 y), (2) parity
(1, 2–4, and $5), (3) birth weight (,2,500 g, 2,500–3,449 g, and
$3,500 g), (4) placental weight (,0.8 and $0.8 kg), (5) any
perinatal surgical procedure (episiotomy and/or perineal tear and
no episiotomy or perineal tear), (6) admission hemoglobin (,
120 g/l and $120 g/l), and (7) body mass index (,25 and $
25 kg/m2). Finally, although our study was fully randomized, we
noted differences between treatment groups in the proportion of
women with the following characteristics: presence of perineal
tears, requirement for episiotomy, and parity. As such, we
performed post hoc analyses to assess for confounding by fitting
multivariable logistic regression models to assess for differences in
our by-treatment estimates after adjustment for these character-
istics. All statistical analyses were performed using STATA version
12.0 (StataCorp, College Station, Texas, US). An independent
data safety monitoring board composed of members at the
Mbarara University of Science and Technology, Makerere
University, and Mbarara Regional Referral Hospital reviewed
preliminary results at 50% (570) and 75% (855) of projected
enrollment, as specified in the protocol, and recommended
continuing study procedures.
Results
Of 8,867 mothers screened for eligibility from 23 September
2012 to 9 September 2013, 4,314 were eligible. A total of 2,369
(55%) declined participation in the study (Figure 1), and 1,140
were enrolled, received a randomized treatment, and completed
study procedures. Demographic and clinical characteristics were
similar between the two treatment groups (Table 1). Primary PPH
occurred in 163 (28.6%) participants in the misoprostol group and
99 (17.4%) participants in the oxytocin group (RR 1.64, 95% CI
1.32 to 2.05, p,0.001; absolute risk difference 11.2%, 95% CI
Misoprostol versus Oxytocin for Prevention of Postpartum Hemorrhage
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6.44 to 16.1; Table 2), corresponding to a number needed to treat
of nine (meaning that nine women would need to be treated with
oxytocin instead of misoprostol to prevent one case of PPH). The
absolute risk difference between the two groups failed to meet the
pre-specified non-inferiority margin of 6%. In stratified analyses to
assess for differences in our primary outcome within sub-groups,
none of the sub-group-by-treatment interaction terms was
significant (Table 3). With the exception of women with parity
$5, all of the point estimates favored oxytocin. Thus, while the
study was not powered to estimate effects within sub-groups, our
results do not suggest differential effects of treatment within
specific sub-groups of mothers.
We found a benefit for oxytocin versus misoprostol in terms of
measured blood loss at 1 and 2 h postpartum (Table 2). The
measured blood loss distribution was skewed to the right for both
those receiving misoprostol (range 46.7–1,557.4 ml; median
457.6 ml) and those receiving oxytocin (range 28.1–1,617.8 ml;
median 410.4 ml) (Figure 2). Importantly, there were no deaths in
either group, and we found no statistically significant difference in
the incidence of severe PPH at 24 h postpartum, which occurred
in 20 (3.6%) participants in the misoprostol group and 15 (2.7%) in
the oxytocin group (RR 1.33, 95% CI 0.69 to 2.58, p=0.391;
absolute risk difference 0.9%, 95% CI 21.12 to 2.88). There was
also no difference in the rate of severe PPH between groups as
estimated at 1 and 2 h postpartum. More mothers in the
misoprostol group than in the oxytocin group received additional
open-label oxytocin (p=0.062). The number of mothers requiring
and receiving a blood transfusion was higher in the oxytocin group
than in the misoprostol group, but the difference did not reach
statistical significance (2.9% versus 1.2%, p=0.058). There were
also no significant differences in hemoglobin change (p=0.075),
mean postpartum hemoglobin (p=0.074), rate of retained
placenta (p=0.378), or duration of the third stage of labor
(p=0.823) (Table 2).
While we performed a randomized control trial and any
differences in baseline characteristics occurred by chance, we did
Figure 1. Trial profile. IM, intramuscular; SL, sublingual.
doi:10.1371/journal.pmed.1001752.g001
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detect baseline differences in parity, requirement for episiotomy, and
requirement for repair of perineal tears between study groups
(Table 1). We assessed for bias from differences in baseline
characteristics between groups by fitting multivariable logistic
regression models. In these models, we found no meaningful
difference in the odds ratio of PPH for misoprostol versus oxytocin
after adjustment for parity, perineal tears, and requirement for
episiotomy (adjusted odds ratio 0.54, 95% CI 0.41 to 0.72, p,0.001).
Side effects were more common in the misoprostol group than
in the oxytocin group. A greater proportion of women in the
misoprostol group than in the oxytocin group experienced
moderate to severe shivering (56.4% versus 26.5%, RR 1.91,
95% CI 1.65 to 2.21, p,0.001), nausea and vomiting (24.2%
versus 15.1%, RR 1.60, 95% CI 1.26 to 2.05, p,0.001), and
temperature .37.5uC (9.3% versus 2.1%, RR 4.42, 95% CI 2.39
to 8.18, p,0.001). Afterpains were more common in the oxytocin
group than in the misoprostol group (p=0.036). No differences
were found between the misoprostol and oxytocin groups in the
rates of diarrhea (p=0.155) or headache (p=0.829).
Discussion
We demonstrated that sublingual misoprostol is inferior to
oxytocin for prevention of primary PPH in women undergoing
uncomplicated vaginal deliveries at a publically funded regional
referral hospital in southwestern Uganda. We found a 64%
increased risk of primary PPH (measured blood loss $500 ml at
24 h) and an absolute risk increase of 11.2% with misoprostol
versus oxytocin. We also found a 33% higher rate of severe PPH
(measured blood loss $1,000 ml) in the misoprostol group,
although this difference was not statistically significant. There
were no maternal deaths in either group. The rates of secondary
outcomes, including mean postpartum hemoglobin, requirement
for additional uterotonics, hemoglobin changes, blood transfusion,
duration of third stage of labor, and retained placenta were similar
in both groups. While not statistically significant, we did observe a
lower absolute rate of blood transfusion and proportion of women
with postpartum hemoglobin ,80 g/l in the misoprostol group.
Our data contribute to a complex array of data on optimal
prevention of PPH in the third stage of labor in resource-limited
settings. Like many prior studies [11], we found a modest benefit
for oxytocin over misoprostol. In summary, we estimate that only
nine women (95% CI 6 to 16) would need to be treated with
oxytocin instead of misoprostol to prevent one case of primary
PPH. On the other hand, our study was restricted to relatively
healthy women without significant co-morbidities, and we
detected no deaths at the time of discharge in either group.
Moreover, we detected a difference in mean measured blood loss
Table 1. Baseline demographic and clinical characteristics by treatment group.
Characteristic Misoprostol Group (n=570) Oxytocin Group (n=570)
Mean age (years) (SD) 29.3 (3.4) 29.7 (3.1)
Educational attainment less than secondary, n (percent) 361 (63.3%) 352 (61.8%)
Parity, n (percent)
1 249 (43.7%) 219 (38.4%)
2–4 273 (47.9%) 286 (50.2%)
$5 47 (8.3%) 64 (11.3%)
Mean gestational age (SD) 39.2 (0.8) 39.3 (0.8)
Mean weight of placenta (SD) 0.6 (0.1) 0.6 (0.1)
Mean duration between previous and current
pregnancy* (years) (SD)
3.7 (2.3) 3.9 (2.2)
Mean birth weight (kg) (SD) 3.1 (0.4) 3.2 (0.5)
Perineal tear, n (percent) 80 (14.0%) 59 (10.4%)
Episiotomy, n (percent) 177 (31.1%) 144 (25.3%)
Mean pre-delivery Hb (g/l) (SD) 131 (14) 132 (13)
Pre-delivery Hb, n (percent)
,120 g/l 85 (14.9%) 76 (13.3%)
,100 g/l 21 (3.7%) 20 (3.5%)
,80 g/l 0 0
History of PPH, n (percent) 65 (11.4%) 66 (11.6%)
Mean hematocrit at admission (n=943) (SD) 39.3 (4.0) 39.6 (4.1)
Prenatal visits (n=1,132), n (percent)
0 0 (0.0%) 2 (0.4%)
1–3 visits 83 (14.7%) 97 (17.2%)
.3 visits 483 (85.3%) 467 (82.5%)
History of home birth*, n (percent) 127 (39.6%) 142 (40.5%)
Mean duration of second stage of labor (minutes) (SD) 13.7 (6.2) 13.4 (6.1)
Total mothers n=570 unless otherwise specified.
*Excludes primigravid mothers.
Hb, hemoglobin; SD, standard deviation.
doi:10.1371/journal.pmed.1001752.t001
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of only 29 ml, 37 ml, and 52 ml at 1, 2, and 24 h postpartum,
respectively, and no differences in other secondary outcomes,
including severe PPH, death, hemoglobin changes, or receipt of a
blood transfusion. Our data therefore signal that, among relatively
healthy women undergoing uncomplicated labor, oxytocin pro-
vides modest benefit over sublingual misoprostol for prevention of
PPH generally, and should be the preferred agent where feasible
and available. However, although we did not include a placebo
arm in our trial, the lack of significant difference in other clinically
significant outcomes between the treatment groups also offers
promising preliminary data that sublingual misoprostol at a dose of
600 mg is likely to be of important benefit where oxytocin is
unavailable. If and whether select populations gain preferential
benefit from oxytocin over misoprostol remains an important
question for further investigation.
Our results are largely consistent with prior studies comparing
misoprostol with oxytocin for prevention of PPH. Only one prior
trial (n=100) specifically compared sublingual misoprostol at the
Table 2. Primary and secondary outcomes by treatment group.
Category Outcome
Misoprostol Group
(n=570)
Oxytocin Group
(n=570) RR (95% CI) p-Value
Absolute Risk
Difference (95% CI)
Primary outcome Blood loss $500 ml
at 24 h
163 (28.6%) 99 (17.4%) 1.64 (1.32 to 2.05) ,0.001 11.2 (6.39 to 16.07)
Secondary outcomes Blood loss $1,000 ml
24 h 20 (3.6%) 15 (2.7%) 1.33 (0.69 to 2.58) 0.391 0.9 (21.12 to 2.88)
2 h 18 (3.2%) 14 (2.5%) 1.29 (0.65 to 2.56) 0.473 0.7 (22.62 to 1.22)
1 h 11 (1.9%) 10 (1.8%) 1.10 (0.47 to 2.57) 0.826 0.1 (21.41 to 1.72)
Blood loss $500 ml
2 h 89 (15.6%) 57 (10.0%) 1.56 (1.14 to 2.13) 0.005 5.6 (1.75 to 9.48)
1 h 53 (9.3%) 35 (6.1%) 1.51 (1.00 to 2.28) 0.046 3.2 (0.06 to 6.25)
.10% Hb dropb 139 (24.4%) 114 (20.0%) 1.22 (0.98 to 1.52) 0.075 4.4 (20.65 to 9.35)
Maternal Hb at
dischargeb
,120 g/l 204 (35.8%) 166 (29.1%) 1.23 (1.04 to 1.44) 0.016 6.7 (1.24 to 12.09)
,100 g/l 48 (8.4%) 49 (8.6%) 0.98 (0.67 to 1.43) 0.916 0.2 (23.23 to 3.43)
,80 g/l 4 (0.7%) 9 (1.6%) 0.44 (0.14 to 1.43) 0.163 0.9 (20.35 to 2.22)
Receipt of blood
transfusion
7 (1.2%) 16 (2.9%) 0.44 (0.18 to 1.06) 0.058 1.7 (20.05 to 3.21)
Use of additional
uterotonics
47 (8.2%) 31 (5.4%) 1.51 (0.98 to 2.35) 0.062 2.8 (20.13 to 5.75)
Retained placenta 5 (0.9%) 4 (0.7%) 1.25 (0.34 to 4.63) 0.738 0.2 (21.07 to 1.04)
Mean blood
loss (ml) (SD)
24 h 484.7 (213.3) 432.8 (203.5) N/A ,0.001 N/A
2 h 341.5 (206.2) 304.2 (190.8) N/A 0.002 N/A
1 h 223.2 (183.1) 193.4 (159.7) N/A 0.004 N/A
Mean postpartum
hematocrit (n=943)
(SD)b
0.361 (0.046) 0.366 (0.048) N/A 0.117 N/A
Mean postnatal
Hb (g/l) (SD)b
120 (14) 121 (15) N/A 0.074 N/A
Mean duration of
third stage of labor
(min) (SD)
4.4 (2.0) 4.4 (1.9) N/A 0.823 N/A
Maternal death 0 0 0 — —
Safety endpoints Headache 10 (1.8%) 11 (1.9%) 0.91 (0.39 to 2.13) 0.829 0.1 (20.04 to 1.07)
Nausea/vomiting 138 (24.2%) 86 (15.1%) 1.60 (1.26 to 2.05) ,0.001 9.1 (4.54 to 13.71)
Fever .37.56C 53 (9.3%) 12 (2.1%) 4.42 (2.39 to 8.18) ,0.001 7.2 (5.05 to 9.38)
Shivering (observed) 321 (56.4%) 168 (26.5%) 1.91 (1.65 to 2.21) ,0.001 29.9 (24.41 to 35.47)
Diarrhea 6 (1.1%) 2 (0.4%) 2.98 (0.60 to 4.72) 0.155 0.7 (20.27 to 1.67)
Afterpains 132 (23.2%) 163 (28.6%) 0.81 (0.66 to 0.99) 0.034 5.4 (0.41 to 10.39)
Data are n (percent) unless otherwise indicated.
bPre-transfusion hemoglobin/hematocrit levels used.
Hb, hemoglobin; N/A, not applicable; SD, standard deviation.
doi:10.1371/journal.pmed.1001752.t002
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routinely used dose of 600 mg to oxytocin at a dose of 10 IU, and
found a lower mean blood loss with oxytocin [27]. A similar study
comparing lower dose sublingual misoprostol with oxytocin 10 IU
found a non-significant decrease in blood loss with oxytocin at 1 h
postpartum [28]. In contrast, another study also comparing low-
dose sublingual misoprostol 400 mg with oxytocin 10 IU found
misoprostol more effective in prevention of PPH at 2 h postpartum
[21]. Importantly, that study used a powdered sublingual
formulation of misoprostol and was unintentionally unblinded
because of lack of proper placebos [29]. Finally, a small study
(n=60) compared sublingual misoprostol 600 mg to syntometrine
in place of oxytocin, and found no difference in PPH between the
two groups [30]. Unlike these prior studies, our study was powered
to demonstrate non-inferiority of a clinical outcome (or lack
thereof) for sublingual misoprostol at a recommended dose of
600 mg versus conventional intramuscular oxytocin 10 IU in
prevention of primary PPH, as defined by WHO (measured blood
loss $500 ml at 24 h postpartum).
While we acknowledge that a recent large systematic review
comparing misoprostol with injectable uterotonics in the manage-
ment of the third stage of labor has been conducted [11], the prior
evidence related to use of sublingual misoprostol 600 mg has been
largely limited by variability of comparator uterotonics, dosing of
study drugs, and heterogeneity of outcome definitions. For
example, in 72 trials discussed in this review (n=52,678), only
663 women received sublingual misoprostol, and only 60 women
did so at the recommended dose of 600 mg [30]. In summary, our
data are the first, to our knowledge, powered to evaluate whether
the routinely used and recommended dosing of sublingual
misoprostol (600 mg) is non-inferior to oxytocin 10 IU for the
outcome of PPH.
Importantly, and in contrast to our study, prior studies have
demonstrated a significantly higher risk of both PPH ($500 ml)
and severe PPH ($1,000 ml) when oral misoprostol is used versus
oxytocin [11]. For example, a large WHO-lead trial [16]
documented a one percentage point difference in blood loss of
$1,000 ml at 1 h postpartum for misoprostol versus oxytocin (4%
versus 3%). This is in contrast to the minimal difference (0.1%) we
detected in measured blood loss at 1 h postpartum (1.9% versus
1.8%). Although we did not directly compare use of oral with
sublingual misoprostol, our results—specifically the relatively small
differences detected in mean measured blood loss, hemoglobin
change, and rates of PPH and severe PPH—support preferential
consideration of sublingual misoprostol over the oral route of
administration. A potential alternative to sublingual administra-
tion of misoprostol in prevention of PPH may be a powdered
formulation of sublingual misoprostol, which has shown superior
efficacy compared to oxytocin [21]. A theoretical advantage of
sublingual misoprostol could be improved bioavailability gained
by evading first-pass metabolism [9].
Another potential explanation for differences between our study
and prior data, which have shown larger effect sizes for differences
between prostaglandins and oxytocin, is our exclusion of women
with cesarean deliveries and multiple pregnancies. Our selection
criteria could underestimate true differences in bleeding risk in the
general population, and specifically in higher risk women.
Table 3. Maternal baseline sub-groups by treatment group with PPH.
Sub-Group (n)
Misoprostol Group
(n=570) Oxytocin Group (n=570) RR (95% CI) p-Value
p-Value for
Interaction Term
Age
18–35 156/549 (28.4%) 92/547 (16.8%) 1.69 (1.34 to 2.12) ,0.001 0.417
.35 7/21 (33.3%) 7/23 (30.4%) 1.10 (0.46 to 2.60) 0.837
Parity
1 79/249 (31.7%) 41/219 (18.7%) 1.69 (1.21 to 2.36) 0.001 0.203
2–4 75/273 (27.5%) 44/286 (15.4%) 1.79 (1.28 to 2.49) 0.001
$5 9/47 (18.8%) 14/64 (21.5%) 0.88 (0.41 to 1.85) 0.726
Birth weight
,2,500 g 4/23 (17.4%) 5/22 (22.7%) 0.77 (0.24 to 2.48) 0.655 0.269
2,500–3499 g 118/423 (27.9%) 62/411 (15.1%) 1.85 (1.40 to 2.44) ,0.001
$3,500 g 41/124 (33.1%) 32/137 (23.4%) 1.42 (0.96 to 2.10) 0.081
Placenta weight
$0.8 kg 24/61 (39.3%) 12/55 (21.8%) 1.80 (1.00 to 3.25) 0.042 0.606
,0.8 kg 139/509 (27.3%) 87/515 (16.9%) 1.62 (1.27 to 2.05) ,0.001
Surgical procedures
Episiotomy/perineal tear 73/204 (35.8%) 32/167 (19.2%) 1.87 (1.30 to 2.68) ,0.001 0.231
No episiotomy or tear 90/366 (24.6%) 67/403 (16.6%) 1.48 (1.11 to 1.96) 0.006
Admission Hb
,120 g/l 26/85 (30.6%) 21/76 (27.6%) 1.11 (0.68 to 1.80) 0.680 0.120
$120 g/l 137/485 (28.2%) 78/494 (15.8%) 1.79 (1.40 to 2.29) 0.000
Body mass index
$25 kg/m2 92/311 (29.6%) 58/308 (18.8%) 1.57 (1.18 to 2.10) ,0.002 0.688
,25 kg/m2 71/259 (27.4%) 41/262 (15.6%) 1.56 (1.11 to 2.20) 0.009
doi:10.1371/journal.pmed.1001752.t003
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Figure 2. Distribution of blood loss and hemoglobin change by treatment arm. (A) Distribution of blood loss by treatment arm. (B) Change
in hemoglobin during hospitalization by treatment arm.
doi:10.1371/journal.pmed.1001752.g002
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We found increased rates of side effects with misoprostol versus
oxytocin, as has been previously reported [11]. Although
misoprostol-related shivering is typically considered a nonserious
side effect, prior studies have reported fever [31,32], secondary
psychological effects including anxiety, and perceptions of lack of
body control [33]. Other concerns have included resultant delays
in blood transfusion, and mimicry of postpartum infection
resulting in unnecessary antibiotic administration, although this
may be uncommon [15].
The benefit of oxytocin over sublingual misoprostol for
prevention of PPH in this trial was seen across most sub-groups.
Effect sizes appeared smaller in certain sub-groups, for example,
women with admission hemoglobin less than 120 g/l, those
older than 35 y, those giving birth to infants with a birth weight
less than 2,500 g, and those with parity greater than four, which
corroborates prior work demonstrating increased risk of PPH
with advanced maternal age, with anemia [34,35], in multip-
arous women, and in women with infants of low birth weight
[36]. Although there were observed differences in point
estimates of PPH incidence in these sub-groups, we found no
significant differences in the effect of the treatment across these
categories.
Our study had a number of strengths. All study investigators
and clinical staff were blinded to treatment allocation. We used
placebos for both oxytocin injection and misoprostol pills.
Although blinding might have been unmasked, particularly by
known side effects (e.g., shivering), we found similar benefit for
oxytocin in a sub-analysis of women without documented
shivering (RR 1.62, 95% CI 1.18 to 2.23, p=0.003). We
performed the study in a prototypical, publically funded and
operated hospital in a rural setting with an active maternity unit,
subject to the standard limitations of public sector health care
facilities in the region. As such, the study has great potential for
generalizability to similar settings.
Our study had some important limitations. We observed a
decrease in maternal PPH from 33% to 17% and in maternal
mortality from 0.12% to 0% from the pre-study period to the
study period, suggesting either presence of strict exclusion criteria,
inaccurate estimation of blood loss in the pre-study period, or
possibility of a Hawthorne effect, which might have resulted from
use of trained MRAs in the study. We also noted clustering of
blood loss measurement between 400 and 500 ml in both groups.
We suspect this was an observer bias stemming from the
prespecified dichotomous outcome of $500 ml over 24 h. While
this might have diminished the overall outcome incidence, our
blinding procedures make it unlikely that measurement error
would bias our estimates.
Another limitation of our study was the observed rate of eligible
participants declining participation (54.9%). A review of stated
reasons for declining participation revealed that most (97%)
participants who declined were disinterested in participating in a
research study, which was perhaps not unexpected given that most
women were presenting in active labor. A recent survey study on
the ward (Dr. Lenard Abesiga, personal communication, 1
November 2012) demonstrated that most mothers on the
maternity ward in this hospital (92%) have little or no knowledge
of medicines administered during labor. Nonetheless, the high
declination rate might introduce a selection bias towards relatively
healthy women.
Conclusion and Recommendations
We found that sublingual misoprostol 600 mg is inferior to
oxytocin 10 IU for prevention of primary PPH during active
management of the third stage of labor among women undergoing
uncomplicated delivery in a rural referral hospital in southwestern
Uganda. Severe PPH was rare in our study population, and we
detected no significant difference between those receiving sublin-
gual misoprostol versus oxytocin (RR 1.33, 95% CI 0.69 to 2.58,
p=0.391). There were also similar rates of changes in postpartum
hemoglobin, duration of the third stage of labor, requirement for
additional uterotonics, and requirement for a blood transfusion.
These data demonstrate that, in settings where it is available,
oxytocin should remain a preferred agent for prevention of PPH.
However, sublingual misoprostol appears to maintain an impor-
tant role for prevention of severe PPH and other complications of
PPH where oxytocin is not available, and reinforces the array of
available interventions for reducing maternal morbidity and
mortality.
Further work should help clarify whether and in which sub-
populations preferential use of oxytocin might have the highest
impact. This is particularly important in resource-limited settings
where storage and availability of oxytocin remains a major
challenge. Additionally, further evaluation of the actual and
perceived barriers to oxytocin use for prevention of PPH in
resource-limited settings will help improve its availability and use
in such settings.
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Editors’ Summary
Background. Every year, nearly 290,000 women die during
pregnancy or labor worldwide, or during the first six weeks
after giving birth (the postpartum period). Almost all of these
‘‘maternal’’ deaths occur in low- or middle-income countries,
and most are caused by a handful of preventable or treatable
conditions—postpartum hemorrhage (severe bleeding from
the uterus [womb] within 24 hours of childbirth), post-
delivery infections, unsafe abortion, obstructive (difficult)
labor, and blood pressure disorders during pregnancy. The
leading cause of maternal deaths worldwide is postpartum
hemorrhage, which is responsible for 25%–30% of all
maternal deaths. Postpartum hemorrhage can be prevented
by giving the mother an intramuscular injection of oxytocin,
a hormone that stimulates uterine contractions and limits
uterine bleeding, immediately after her child is born.
Why Was This Study Done? Unfortunately, oxytocin
needs to be kept cool, which limits its use in low- and
middle-income countries, and, until recently, it was thought
that only trained personnel could give intramuscular
injections. Consequently, administration of misoprostol, a
synthetic prostaglandin that has effects similar to those of
oxytocin, has been proposed as an alternative way to
prevent postpartum hemorrhage in resource-limited set-
tings. Misoprostol is stable at room temperature, and
because it can be given sublingually (below the tongue), it
acts very quickly. However, the comparative efficacy of
sublingual misoprostol and intramuscular oxytocin for the
prevention of postpartum hemorrhage has not been
established. Here, the researchers undertake a double-
blinded, double-dummy randomized controlled non-inferi-
ority trial to compare sublingual misoprostol and intramus-
cular oxytocin for the prevention of postpartum hemorrhage
in Uganda, a country where there are more than 5,500
maternal deaths every year. A randomized controlled trial
compares the outcomes of individuals assigned to different
interventions through the play of chance. In a double-
blinded trial, neither the researchers nor the participants
know who is receiving which intervention. In this particular
trial, double-blinding is achieved by giving a dummy
(placebo) sublingual pill to the women assigned to the
oxytocin group and a dummy injection to the women
assigned to the misoprostol group, as well as their assigned
treatments. A non-inferiority trial investigates whether one
treatment is not worse than another treatment.
What Did the Researchers Do and Find? The researchers
measured blood loss over the first 24 hours after delivery in
1,140 women admitted to a regional referral hospital in
Uganda. The women were given either sublingual misopros-
tol or intramuscular oxytocin at the currently recommended
doses, along with matching placebos, immediately after the
birth of their child. Postpartum hemorrhage (defined as the
loss of more than 500 ml of blood within 24 hours of
delivery; the trial’s primary outcome) occurred in 28.6% and
17.4% of the women in the misoprostol and oxytocin groups,
respectively (an absolute risk difference of 11.2%). Severe
postpartum hemorrhage (loss of more than 1,000 ml of
blood within 24 hours of delivery) occurred in 3.6% and 2.7%
of participants in the misoprostol and oxytocin groups,
respectively, but this difference was not statistically signif-
icant (it could have happened by chance). On average,
women given misoprostol had lost slightly more blood by
two and 24 hours after delivery than those given oxytocin.
There were no significant differences between the groups in
terms of death, the need for blood transfusion, or the use of
additional drugs to prevent blood loss, but women given
misoprostol experienced shivering and fever more often
than those given oxytocin.
What Do These Findings Mean? In their study protocol,
the researchers specified that sublingual misoprostol would
be deemed non-inferior to intramuscular oxytocin if the
absolute risk difference for postpartum hemorrhage be-
tween the misoprostol and oxytocin treatment groups was
less than 6% (the ‘‘non-inferiority’’ margin). These findings
therefore indicate that sublingual misoprostol given at the
recommended dose is inferior to intramuscular oxytocin for
the prevention of postpartum hemorrhage in women
undergoing an uncomplicated birth at a regional referral
hospital in Uganda. Although several aspects of this study
may affect the accuracy and generalizability of its findings
(for example, women at high risk of birth complications were
excluded from the study), the researchers conclude that
oxytocin should remain the preferred agent for the preven-
tion of postpartum hemorrhage where it is available.
However, they note, sublingual misoprostol remains impor-
tant for the prevention of postpartum hemorrhage where
oxytocin is unavailable or its administration is not feasible.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001752.
N The United Nations Children’s Fund (UNICEF) provides
information on maternal mortality; ‘‘Trends in Maternal
Mortality: 1990 to 2013’’ is a recent WHO/UNICEF/UNFPA/
World Bank publication that provides up-to-date informa-
tion on maternal mortality worldwide
N The World Health Organization provides information on
maternal health (in several languages)
N The Postpartum Hemorrhage Prevention and Treatment
Website provides a forum for information sharing and
learning between organizations and individuals working
on the prevention and treatment of postpartum hemor-
rhage in developing countries; the website includes basic
information about postpartum hemorrhage and links to
additional resources
N ‘‘Veil of Tears’’ contains personal stories (including stories
about postpartum hemorrhage) from Afghanistan about
loss in childbirth
N ‘‘Maternal Death: The Avoidable Crisis’’ is a briefing paper
published by Me´decins Sans Frontie`res in 2012
N More information about this trial is available
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